These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3962752)

  • 1. Orphenadrine plasma levels and amelioration of extrapyramidal side effects in schizophrenic patients treated with haloperidol.
    Altamura AC; Buccio M; Colacurcio F; Colombo G; Terzi A
    Acta Neurol (Napoli); 1986 Feb; 8(1):19-26. PubMed ID: 3962752
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination therapy with haloperidol and orphenadrine in schizophrenia. A clinical and pharmacokinetic study.
    Altamura AC; Buccio M; Colombo G; Terzi A; Cazzullo CL
    Encephale; 1986; 12(1):31-6. PubMed ID: 3698889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A double-blind study of metoclopramide in the treatment of schizophrenia and determination of prolactin].
    Gu SF
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1992 Dec; 25(6):328-30, 382. PubMed ID: 1304992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma haloperidol levels drawn at neuroleptic threshold doses: a pilot study.
    McEvoy JP; Stiller RL; Farr R
    J Clin Psychopharmacol; 1986 Jun; 6(3):133-8. PubMed ID: 3711363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biperiden and haloperidol plasma levels and extrapyramidal side effects in schizophrenic patients.
    Meszaros K; Lenzinger E; Hornik K; Schönbeck G; Hatzinger R; Langer G; Sieghart W; Aschauer HN
    Neuropsychobiology; 1997; 36(2):69-72. PubMed ID: 9267855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses.
    Cesková E; Svestka J
    Pharmacopsychiatry; 1993 Jul; 26(4):121-4. PubMed ID: 7694306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extrapyramidal side effects and oral haloperidol: an analysis of explanatory patient and treatment characteristics.
    Moleman P; Schmitz PJ; Ladee GA
    J Clin Psychiatry; 1982 Dec; 43(12):492-6. PubMed ID: 7161250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of extrapyramidal side effects of haloperidol through the joint use of imipramine-type drugs.
    Butterworth AT
    Psychosomatics; 1972; 13(5):328-32. PubMed ID: 4671924
    [No Abstract]   [Full Text] [Related]  

  • 9. [Standard and high doses of haloperidol. Clinical, pharmacokinetic and pharmacodynamic aspects].
    Schilkrut R; Haverbeck C; Duran E; Delgado S; Kohen P; Birkner R; Katz I
    Acta Psiquiatr Psicol Am Lat; 1981; 27(4-5):315-24. PubMed ID: 7348089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Residual neuroleptic-induced parkinsonian symptoms in schizophrenia. A naturalistic study with orphenadrine.
    Altamura AC; Mauri MC; De Novellis F; Percudani M; Vampini V
    Pharmacopsychiatry; 1989 Nov; 22(6):246-9. PubMed ID: 2616635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial effects of dantrolene in the treatment of neuroleptic malignant syndrome: a report of two cases.
    Goulon M; de Rohan-Chabot P; Elkharrat D; Gajdos P; Bismuth C; Conso F
    Neurology; 1983 Apr; 33(4):516-8. PubMed ID: 6682201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The use of nifedipine as a corrector of extrapyramidal side-effects of classical neuroleptics].
    Popov MIu
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(6):28-33. PubMed ID: 18577931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms.
    Timdahl K; Carlsson A; Stening G
    Hum Psychopharmacol; 2007 Jul; 22(5):315-25. PubMed ID: 17542047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effects of haloperidol.
    Man PL
    Dis Nerv Syst; 1973 Feb; 34(2):113-8. PubMed ID: 4267586
    [No Abstract]   [Full Text] [Related]  

  • 15. [Acute-onset extrapyramidal syndromes caused by drugs].
    Montoya Cabrera MA; López Martín G; Baca Rodríguez LC; Porcayo Vergara F; Hernández Zamora A; Juárez Aragón G
    Bol Med Hosp Infant Mex; 1981; 38(4):607-15. PubMed ID: 6117295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haloperidol in overt ambulatory schizophrenics.
    Darling HF
    Dis Nerv Syst; 1973; 34(7):364-7. PubMed ID: 4782293
    [No Abstract]   [Full Text] [Related]  

  • 17. Open study with bromperidol (C-C 2489), a new neuroleptic, for the determination of the neuroleptic threshold and the neuroleptic-therapeutic range.
    Haase HJ; Kaumeier S; Schwarz H; Gundel A; Linde OK; Maetz H; Scheel R; Stripf A; Stripf L
    Pharmakopsychiatr Neuropsychopharmakol; 1978 Mar; 11(2):81-5. PubMed ID: 643910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Symptom change and extrapyramidal side effects during acute haloperidol treatment in chronic geriatric schizophrenics.
    Weisbard JJ; Pardo M; Pollack S
    Psychopharmacol Bull; 1997; 33(1):119-22. PubMed ID: 9133762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Testing basic visual functions in the evaluation of extrapyramidal side effects of antipsychotic agents].
    Kéri S; Antal A; Szekeres G; Szendi I; Kovács Z; Janka Z; Benedek G
    Orv Hetil; 1998 Feb; 139(5):235-8. PubMed ID: 9489377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extrapyramidal reactions to prochlorperazine and haloperidol in the United Kingdom.
    Bateman DN; Rawlins MD; Simpson JM
    Q J Med; 1986 Jun; 59(230):549-56. PubMed ID: 3749448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.